STOCK TITAN
  1. Home
  2. News
  3. PRTC

PureTech Health Plc - PRTC STOCK NEWS

Welcome to our dedicated news page for PureTech Health Plc (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on PureTech Health Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PureTech Health Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PureTech Health Plc's position in the market.

News
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced favorable safety profile and anti-tumor activity of LYT-200 in combination with tislelizumab. Initial results show promise for patients with head and neck cancers, where historical outcomes are poor with response rates of less than 20 percent on standard-of-care treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
clinical trial
-
News
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Rhea-AI Summary
Karuna Therapeutics (KRTX) announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia. KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, ruling out a clinically meaningful increase in blood pressure. The trial showed that KarXT was generally well tolerated, with a side effect profile consistent with prior trials in the EMERGENT program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
-
News
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced topline results from its Phase 2a trial of LYT-300, an oral allopregnanolone, demonstrating a statistically significant reduction in the stress hormone response compared to placebo. LYT-300 has the potential to address drawbacks in current anxiety disorder treatments and was well-tolerated in the trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
PureTech to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
PureTech Health announces third quarter progress and upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
News
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
Rhea-AI Summary
PureTech Health presents clinical data supporting the differentiated profile of LYT-100 at the CHEST Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
Rhea-AI Summary
Vedanta Biosciences announces first patient dosed in Phase 2 clinical trial of VE202 for the treatment of ulcerative colitis and receives Fast Track designation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
clinical trial
-
News
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Rhea-AI Summary
Karuna Therapeutics submits NDA to FDA for KarXT for schizophrenia treatment, could be first new mechanism in over 50 years if approved
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
fda approval
News
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
Rhea-AI Summary
PureTech Health plc appoints Robert Lyne as Chief Portfolio Officer, bringing a decade of experience in international life science deals and portfolio management. His appointment is expected to strengthen PureTech's senior leadership team and complement their business model. PureTech looks forward to realizing the full potential of their programs and stakes and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock PRTC logo
PureTech Health Plc

Nasdaq:PRTC

PRTC Rankings

#2654 Ranked by Market Cap
#3907 Ranked by Stock Gains
N/A Ranked by Dividends

PRTC Stock Data

734.36M
154.84M
0.04%
0.02%
Investment Advice
Finance and Insurance
Link
US
Boston

About PRTC

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.